MwanzoB1NT34 • BVMF
BioNTech SE
R$ 44.92
30 Jan, 21:45:11 GMT -3 · BRL · BVMF · Kanusho
Hisa zinazouzwa BR
Bei iliyotangulia
R$ 44.60
Bei za siku
R$ 44.05 - R$ 45.30
Bei za mwaka
R$ 26.80 - R$ 49.05
Thamani ya kampuni katika soko
28.98B USD
Wastani wa hisa zilizouzwa
382.00
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
(EUR)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Mapato
1.24B39.04%
Matumizi ya uendeshaji wa biashara
1.04B53.43%
Mapato halisi
198.10M23.35%
Kiwango cha faida halisi
15.91-11.32%
Mapato kwa kila hisa
0.8120.90%
EBITDA
65.30M-30.31%
Asilimia ya kodi ya mapato
-24.83%
Jumla ya mali
Jumla ya dhima
(EUR)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Uwekezaji wa pesa taslimu na vipindi vifupi
16.71B6.10%
Jumla ya mali
22.40B0.87%
Jumla ya dhima
3.29B40.43%
Jumla ya hisa
19.11B
hisa zilizosalia
239.74M
Uwiano wa bei na thamani
0.56
Faida inayotokana na mali
0.23%
Faida inayotokana mtaji
0.27%
Mabadiliko halisi ya pesa taslimu
(EUR)Sep 2024Mabadiliko Tangu Mwaka Uliopita
Mapato halisi
198.10M23.35%
Pesa kutokana na shughuli
-638.90M-178.76%
Pesa kutokana na uwekezaji
-142.10M88.47%
Pesa kutokana na ufadhili
-7.90M97.46%
Mabadiliko halisi ya pesa taslimu
-752.10M-12.12%
Mtiririko huru wa pesa
-684.45M-217.91%
Kuhusu
BioNTech SE is a global biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases. The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes. In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2008
Wafanyakazi
6,133
Tafuta
Futa utafutaji
Funga kisanduku cha kutafutia
Programu za Google
Menyu kuu